• Mashup Score: 3

    This webinar will include a sampling of patient advocate research abstracts from presented at the 2023 IASLC World Conference on Lung Cancer (WCLC23) in Singapo …

    Tweet Tweets with this article
    • Join us for an IASLC/STARS webinar including sampling of patient advocate research abstracts presented during #WCLC23 & a live Q&A session moderated by #lungcancer patient/research advocate @JFreemanDaily: https://t.co/J8KHKBDcZ9 #LCSM @jillfeldman4 @BairdAM @ProjectBreath #LCSM https://t.co/cewKBNkojf

  • Mashup Score: 1

    Dr. Navneet Singh, MD DM (India) will moderate the program and lead the discussion and Q&A following panel presentations by Christian Rolfo, MD, Ph.D., MBA (USA …

    Tweet Tweets with this article
    • Last Call! Join us tomorrow for the IASLC Webinar: "2023 WCLC Highlights" w/@ns_chd, @ChristianRolfo, @cbaldotto & @HendriksLizza to discuss EGFRm advanced #NSCLC (FLAURA2), I-SABR study, AEGEAN & much more! https://t.co/DIeKJqLpH4 #LCSM #WCLC23 https://t.co/QdFnFA0owx

  • Mashup Score: 0

    First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR) -mutated non–small cell lung cancer (NSCLC), according to the findings of the phase III FLAURA2 study. These results were presented by Pasi A. Jänne, MD, PhD, of the Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston,

    Tweet Tweets with this article
    • FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC https://t.co/TJfjEwu77q #LCSM #lungcancer #oncology #WCLC23

  • Mashup Score: 0

    Alan Sihoe, MBBChir, FRCSEd, FCSHK, FHKAM, The University of Hong Kong, Pokfulam, Hong Kong, shares an overview and the benefits of video-assisted thoracic surgery (VATS) for lung cancer management. VATS is a modern minimally invasive surgery that has been beneficial for lung cancer patients who are usually ineligible for surgical therapies. Current goals are to make the surgery less invasive and to ensure enhanced recovery after surgery (ERAS). VATS can also complement pharmacological advances as the time between the procedure and post-operative adjuvant therapy can be significantly reduced. Research has also revealed that circulating tumour (ct)-DNA after VATS may be a useful biomarker for survival, where a lower quantity of ct-DNA after the procedure is associated with better clinical outcomes in adjuvant immunotherapy. Dr Sihoe comments that surgeons are continuously finding useful roles for VATS in lung cancer management. This interview took place at the 2023 World Conference on L

    Tweet Tweets with this article
    • 🎥@ASihoe of @HKUniversity highlights the advantages of Video-Assisted Thoracic Surgery (VATS) in #lungcancer management, promoting less invasiveness and faster recovery: ➡️https://t.co/3SRWS83Dnj⬅️ #WCLC23 #LCSM #SurgOnc

  • Mashup Score: 0

    Seshiru Nakazawa, MD, PhD, of Dana-F arber Cancer Institute, discusses activating the MET tyrosine kinase domain mutation, which has been identified as the sole oncogenic mutation in a small but significant subset of patients with non–small cell lung cancer (NSCLC). According to Dr. Nakazawa’s findings, this mutation is potentially targetable with currently available MET tyrosine kinase inhibitors. Yasir Y. Elamin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the

    Tweet Tweets with this article
    • Seshiru Nakazawa, MD, PhD, on NSCLC and Point Mutations as de Novo Oncogenic Drivers https://t.co/oV4T7ylUZ0 #LCSM #lungcancer #oncology #WCLC23 @DanaFarber @DanaFarberNews

  • Mashup Score: 4

    Dr. Navneet Singh, MD DM (India) will moderate the program and lead the discussion and Q&A following panel presentations by Christian Rolfo, MD, Ph.D., MBA (USA …

    Tweet Tweets with this article
    • Looking forward to discuss tomorrow the highlights of #WCLC23 @IASLC with a great faculty! @cbaldotto @HendriksLizza and @ns_chd ! FLAURA2, AEGEAN, new TNM 9 Classification, PD-L1 tumor cell scoring and more https://t.co/a8U7jFo5V7 @isliquidbiopsy @TischCancer @LUNGevity https://t.co/0xqJXDk33X

  • Mashup Score: 1

    Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, comments on four presentations from the 2023 World Conference on Lung Cancer for which he served as discussant: the global landscape of three types of lung cancer (squamous cell, adenocarcinoma, and small cell); findings from the Australian Registry and Biobank of Thoracic Cancers; the Registry of Genetic Alterations of Taiwan by comprehensive next-generation sequencing; and treatment decisions

    Tweet Tweets with this article
    • RT @ASCOPost: Gilberto de Lima Lopes, Jr, MD, MBA, on Lung Cancer Management: Expert Update https://t.co/zvm1Kk2C8d #WCLC23 #LCSM #lungcanc…

  • Mashup Score: 1

    Ilias Houda, MD, PhD Candidate, of A msterdam University Medical Centers, discusses the differing opinions of thoracic surgeons when it comes to resection for stage III non–small cell lung cancer (NSCLC). The international EORTC survey showed there is no consensus, although respondents were more likely to consider some stage III TNM combinations to be potentially resectable. Chee K. Lee, PhD, MBBS, of the University of Sydney, discusses findings of the ILLUMINATE study, which showed d urvalumab and

    Tweet Tweets with this article
    • Ilias Houda, MD, PhD Candidate, on Results of an EORTC Survey on NSCLC Resectability https://t.co/uMt4ZZ4gTZ #LCSM #lungcancer #WCLC23 @amsterdamumc

  • Mashup Score: 0

    Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses resul ts of the VISION trial, the largest on-treatment liquid biopsy biomarker data set of a MET inhibitor in patients with MET exon 14 non–small cell lung cancer (NSCLC). Tepotinib showed durable efficacy in this population. Chee K. Lee, PhD, MBBS, of the University of Sydney, discusses findings of the ILLUMINATE study, which showed d urvalumab and tremelimumab with chemotherapy yielded antitumor activity in patients

    Tweet Tweets with this article
    • Xiuning Le, MD, PhD, on Update on the Use of Tepotinib to Treat an NSCLC Subset https://t.co/gnDhcSPbkt #LCSM #lungcancer #WCLC23 #genetics @MDAndersonNews @LeXiuning

  • Mashup Score: 1

    Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, comments on four presentations from the 2023 World Conference on Lung Cancer for which he served as discussant: the global landscape of three types of lung cancer (squamous cell, adenocarcinoma, and small cell); findings from the Australian Registry and Biobank of Thoracic Cancers; the Registry of Genetic Alterations of Taiwan by comprehensive next-generation sequencing; and treatment decisions

    Tweet Tweets with this article
    • Gilberto de Lima Lopes, Jr, MD, MBA, on Lung Cancer Management: Expert Update https://t.co/zvm1Kk2C8d #WCLC23 #LCSM #lungcancer #oncology @GlopesMd @SylvesterCancer @UnivMiami